Table 5. Prognostic value of the pattern of statin therapy use for total adverse events at 6-month follow up.

Grouping	Hazard ratio (95% CI)
	Unadjusted	P	Adjusted	P
Group I	1		1
Group II	3.19 (1.21–8.42)	0.019	3.2 (1.31–7.86)	0.011
Group III	4.77 (1.71–13.28)	0.003	3.84 (1.47–10.02)	0.006
Group IV	3.71 (1.71–8.0)	0.001	3.17 (1.59–6.40)	0.001

Adjusted for age, gender, Killip class > I, blood pressures, left ventricular ejection fraction < 45%, and co-morbidities (previous myocardial infarction, angina pectoris, heart failure, hypertension, diabetes, smoking history, increased lipid levels, stroke, and peripheral vascular disease), medications before and after discharge, reperfusion therapies (primary percutaneous coronary intervention, thrombolytic therapy, and overall percutaneous coronary intervention), angiographic findings (multivessel disease, target vessel, lesion type C, and stent insertion), and complications. Patterns of statin therapy use: Group I, statin therapy both during hospitalization and after discharge; Group II, only during hospitalization; Group III, only after discharge; and Group IV, no statin therapy.